Mito-apocynin (C2), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C2) exhibits antineuroinflammatory effect[1].
Mito-apocynin (C2) (3 mg/kg; p.o.; daily for 12 days) exhibits antineuroinflammatory effect[1]. Animal Model: MPTP mice model of Parkinson's Disease[1]
[1]. Zielonka J, et al. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017 Aug 9;117(15):10043-10120.